Sobi Sets Ambitious 2030 Target to Double Revenue on Wave of New Rare-Disease Launches

Swedish Orphan Biovitrum AB ( (SE:SOBI) ) has issued an update.

Sobi used its 2026 Capital Markets Day to outline an ambitious plan to double revenue to SEK 55 billion by 2030, targeting an adjusted EBITA margin in the upper 30s while keeping R&D spending at 11–14% of sales. Management said growth will be driven by six major product launches, continued strength in strategic therapies and broader international expansion, underlining the company’s shift into a more diversified, globally scaled rare-disease player.

The company highlighted a pipeline it says can sustain growth beyond 2030, with new peak sales targets for key drugs in haemophilia A, complement-mediated diseases, hyperinflammation, gout and other specialty indications that, in several cases, exceed SEK 10 billion. Deep-dive data on gout, severe hypertriglyceridemia and precision medicine in sepsis showcased Sobi’s push into areas of high unmet medical need, signalling greater scientific ambition and potentially meaningful future value for patients, investors and healthcare systems if the programmes succeed.

The most recent analyst rating on (SE:SOBI) stock is a Buy with a SEK475.00 price target. To see the full list of analyst forecasts on Swedish Orphan Biovitrum AB stock, see the SE:SOBI Stock Forecast page.

More about Swedish Orphan Biovitrum AB

Swedish Orphan Biovitrum AB, or Sobi, is a global biopharmaceutical company focused on breakthrough treatments for rare diseases across haematology, immunology and specialty care. Headquartered in Stockholm and listed on Nasdaq Stockholm, the company generated SEK 28 billion in revenue in 2025 and employs around 1,900 people across Europe, North America, the Middle East, Asia and Australia.

Average Trading Volume: 444,742

Technical Sentiment Signal: Buy

Current Market Cap: SEK140.6B

For a thorough assessment of SOBI stock, go to TipRanks’ Stock Analysis page.